Novartis has deepened its partnership with Shanghai-based Argo Biopharma, signing a new deal valued at up to $5.2 billion, including $160 million upfront payments and substantial milestones. This third agreement focuses on Argo’s RNA interference (RNAi) therapy candidates targeting severe hypertriglyceridemia and mixed dyslipidemia. Novartis gains rights outside China for several discovery-stage molecules and an investigational drug in Phase 2 trials. The partnership exemplifies the accelerating engagement of global pharma firms with China's biotech sectors, leveraging innovative RNA-based treatment modalities.